MEDICAL DISCLAIMER: Educational research guidelines only. Lyophilized peptides are investigational chemical compounds and are NOT approved for human consumption, diagnosis, or therapy. Consult a licensed physician before any research application.
Eloralintide Dosage Chart, Schedule & Reconstitution Protocol
Quickstart Highlights
Eloralintide (LY3841136) is an investigational long-acting selective amylin-1 receptor (AMY1R) agonist from Eli Lilly for weight management. It is a 37-amino-acid amylin analog stabilized with a methylene-thioacetal bridge and acylated with a C20 fatty-diacid chain for albumin binding, giving a ~13–15 day half-life and once-weekly subcutaneous dosing (PMID 41109426). In a 48-week Phase 2 trial of 263 adults with obesity (NCT06230523), once-weekly doses of 1, 3, 6 and 9 mg produced mean weight loss of about 9% to 20% versus 0.4% with placebo, with mostly mild-to-moderate gastrointestinal effects and fatigue that eased with gradual escalation (PMID 41207310). Unlike many compounds on this site, its real clinical route genuinely is subcutaneous, so the reconstitution figures track real use. Eloralintide is not FDA- or EMA-approved; it is investigational, and this content is educational only, not medical advice.
Reconstitute: Add 3 mL bacteriostatic water → 10 mg/mL concentration.
Typical dose: 1–9 mg once weekly subcutaneously (Phase 2 trial range)
Easy measuring: At 10 mg/mL, 1 unit = 0.01 mL = 0.1 mg (100 mcg) on a U-100 insulin syringe.
Storage: Lyophilized powder stored frozen at −20 °C, protected from light. Reconstituted solution refrigerated at 2–8 °C and used within about 4 weeks. Avoid freeze-thaw cycling of the mixed solution; do not shake.
Half-life: Approximately 310–366 hours (about 13–15 days); Tmax ~72–132 h. Accumulates over several weeks of weekly dosing, supporting once-weekly subcutaneous injection.
Route: Once-weekly subcutaneous injection — the genuine clinical route. Modeled here as a 30 mg vial in 3.0 mL bacteriostatic water (10 mg/mL): 1 mg ≈ 10 units, 9 mg ≈ 90 units on a U-100 syringe.
Status: Investigational (Eli Lilly); completed Phase 1 and Phase 2, Phase 3 planned. Not FDA- or EMA-approved. Research/educational use only, not medical advice.
About Eloralintide
Eloralintide (LY3841136) is an investigational, long-acting selective amylin-1 receptor (AMY1R) agonist from Eli Lilly being developed as a once-weekly subcutaneous injection for weight management [1][2]. Unlike many compounds catalogued on this site, its real-world clinical route genuinely is subcutaneous, so the reconstitution figures below map directly onto how the drug was actually administered in trials. There is no oral form; the molecule is a fatty-acid-acylated peptide designed for weekly depot dosing [1].\n\nThe Eloralintide dosage tested in the Phase 2 obesity program (NCT06230523) used fixed once-weekly subcutaneous doses of 1 mg, 3 mg, 6 mg and 9 mg, along with stepwise escalation arms (3→9 mg and 6→9 mg) intended to improve gastrointestinal tolerability [2][3]. Phase 1 single-dose work explored a wider 0.04–12 mg range [1]. Because the compound carries an unusually long half-life of roughly 13–15 days, plasma levels accumulate over the first several weeks and once-weekly dosing produces stable, slowly rising exposure [1].\n\nThis guide models a 30 mg vial reconstituted with 3.0 mL of bacteriostatic water (10 mg/mL), so each weekly dose lands on a clean, measurable mark on a U-100 insulin syringe: 1 mg ≈ 10 units, 3 mg ≈ 30 units, 6 mg ≈ 60 units and 9 mg ≈ 90 units. A gradual climb from 1 mg toward the higher maintenance doses mirrors the escalation strategy used in the trial to limit nausea [2][3].\n\nFrequency: Inject once weekly subcutaneously, on the same day each week, rotating sites. Eloralintide is not FDA- or EMA-approved and is presented here for educational purposes only.
Quick Protocol Navigation
Reconstitution Instruction & Mixing Step-by-Step
Lyophilized powder must be reconstituted carefully. Agitating peptide chains can shear disulfide bonds and render the peptide biologically inert.
Draw 3.0 mL of bacteriostatic water into a sterile syringe (this yields a 10 mg/mL solution from a 30 mg vial, so 1 insulin-syringe unit = 100 mcg).
Inject the water slowly down the inner wall of the vial; do not aim the stream directly at the lyophilized powder, and do not shake, as agitation can denature the peptide.
Gently swirl or roll the vial until the solution is completely clear; the result is 10 mg/mL.
Store refrigerated at 2–8 °C and draw the prescribed weekly dose: 1 mg ≈ 10 units, 3 mg ≈ 30 units, 6 mg ≈ 60 units, 9 mg ≈ 90 units on a U-100 syringe.
Swab the injection site (abdomen, thigh, or upper arm), inject subcutaneously once weekly, rotate sites each week, and return the vial to the refrigerator.
Interactive Eloralintide Syringe Calculator
Currently visualizing the 30 mg vial reconstituted with 3 mL bacteriostatic water. Adjust the target dose to dynamically render syringe units.
Reconstitution Calculation: 30mg dry powder in 3mL water yields 10.00 mg/mL. To evaluate a 250mcg dose, pull to 2.5 units (3 syringe ticks).
U-100 Syringe Representation
Educational reference visual. Assumes standard U-100 insulin syringe where 1.0 mL volume = 100 units.
Titration & Dose Escalation Schedules
| Phase | Dose per injection | Units (per injection) |
|---|---|---|
| Weeks 1-4 — initiation (1 mg) | 1000 mcg (1 mg) | 10 units (0.10 mL) |
| Weeks 5-8 — first step-up (3 mg) | 3000 mcg (3 mg) | 30 units (0.30 mL) |
| Weeks 9-12 — mid maintenance (6 mg) | 6000 mcg (6 mg) | 60 units (0.60 mL) |
| Week 13+ — top trial dose (9 mg) | 9000 mcg (9 mg) | 90 units (0.90 mL) |
Administration guidelines: Refer to guidelines | 3 mL Reconstitution
Research Supplies Quantity Planner
Scientific mathematical planning of syringes, bacteriostatic water and dry vials needed for extended research blocks using the 30 mg vial.
Peptide Vials (Eloralintide, 30 mg each):
- check8-week titration (1→3 mg) uses only ~16 mg of drug, but the ~4-week in-use stability limit means ≈2-3 vials
- check12-week course (1→6 mg) uses ~40 mg of drug ≈ 3-4 vials accounting for partial-vial discards
- check16-week course (1→9 mg) uses ~76 mg of drug ≈ 4-5 vials; the low weekly usage versus the 4-week stability window is why partial vials are discarded
Insulin Syringes (U-100):
- checkOnce-weekly dosing: 1 syringe per week, plus 1 syringe per vial for reconstitution
- check8 weeks ≈ 8 injection syringes (+ ~3 for mixing); 12 weeks ≈ 12 (+ ~4)
- check16 weeks ≈ 16 injection syringes (+ ~5 for mixing)
Bacteriostatic Water (30 mL bottles): Use 3 mL per 30 mg vial for reconstitution.
- check8 weeks (≈2-3 vials) ≈ 6-9 mL — well under one bottle
- check12 weeks (≈3-4 vials) ≈ 9-12 mL — under one bottle
- check16 weeks (≈4-5 vials) ≈ 12-15 mL — a single 30 mL bottle covers a full course
Alcohol Swabs:
- check1-2 swabs per weekly dose (vial top + injection site)
- check8 weeks ≈ 16-24 swabs; 12 weeks ≈ 24-36 swabs
- check16 weeks ≈ 32-48 swabs; keep extras for re-swabbing multi-dose vials
Mechanism of Action (MOA)
Eloralintide is a synthetic, long-acting analog of the pancreatic hormone amylin (islet amyloid polypeptide), engineered by Eli Lilly for selective, durable activation of the amylin-1 receptor (AMY1R) [1]. Native amylin is a 37-amino-acid peptide co-secreted with insulin that signals satiety, slows gastric emptying and suppresses postprandial glucagon, but it aggregates into amyloid and is cleared within minutes, making it unusable as a weekly drug. Eloralintide retains the 37-residue amylin scaffold but incorporates three non-coded amino-acid residues, replaces amylin's native disulfide bond with a more stable methylene-thioacetal bridge, and adds a C20 fatty-diacid chain at lysine-26 that binds reversibly to serum albumin [1]. That acylation is what converts a minutes-long hormone into a once-weekly therapeutic.\n\nAmylin receptors are heterodimers of the calcitonin receptor (CTR) paired with receptor-activity-modifying proteins (RAMP1/2/3), generating AMY1, AMY2 and AMY3 subtypes. In vitro, eloralintide is a full agonist that is roughly 12-fold more potent at human AMY1R than at the bare calcitonin receptor and about 11-fold more potent at AMY1R than at AMY3R [1]. This selectivity distinguishes it from non-selective dual amylin/calcitonin agonists such as cagrilintide, and preclinically it produced robust weight loss with less conditioned taste aversion than cagrilintide, suggesting the favorable tolerability may be mechanistically linked to its receptor profile [1]. Downstream, AMY1R signaling in the hindbrain (area postrema and nucleus tractus solitarius) and hypothalamic circuits enhances satiation and reduces food intake — a pathway complementary to, and distinct from, GLP-1 receptor agonism, which is why amylin agonists are being studied both as monotherapy and combined with incretins like tirzepatide [2][3]. Amylin's classic actions of delayed gastric emptying and glucagon suppression are well characterized for the approved short-acting analog pramlintide [6][7].\n\nPharmacokinetically, eloralintide is administered by once-weekly subcutaneous injection. Across human doses it shows a median time to peak concentration (Tmax) of roughly 72–132 hours and a terminal half-life of approximately 310–366 hours, or about 12.9–15.3 days, with exposure (AUC) that is approximately dose-proportional from 0.4 to 12 mg [1]. The very long half-life means plasma concentrations accumulate over the first several weeks of weekly dosing before reaching steady state, which underpins the gradual dose-escalation strategy used in clinical studies to blunt early gastrointestinal effects [2][3].\n\nEloralintide is a genuine subcutaneous, weekly-injection compound, so the reconstitution scheme on this page reflects its real route of administration; the only difference from clinical use is that trials employ pharmaceutical-grade prefilled product rather than research-grade lyophilized powder. It is an investigational molecule that has completed Phase 1 and Phase 2 testing and is not approved by any regulator [2][4].
Clinical Trial Efficacy Highlights
- starBriere and colleagues (Molecular Metabolism, 2025) reported eloralintide's discovery-to-proof-of-concept profile: in vitro it is a full AMY1R agonist about 12-fold more potent at human AMY1R than the calcitonin receptor and ~11-fold more potent than AMY3R, and in diet-induced obese rats dosed every three days it produced roughly a 12.3% body-weight reduction by day 13, with fat loss accounting for 68–86% of total weight loss [1].
- starIn the first-in-human Phase 1 study (48 healthy adults, mean BMI 27.5), single subcutaneous doses of eloralintide were generally well tolerated, with nearly all treatment-emergent adverse events mild and only 2 of 36 dosed participants reporting gastrointestinal events; single 4 mg and 12 mg doses produced placebo-adjusted weight reductions of −2.5% and −4.4% by day 29, respectively [1].
- starHuman pharmacokinetic characterization showed a terminal half-life of approximately 310–366 hours (about 13–15 days), a median Tmax of 72–132 hours, and approximately dose-proportional AUC across 0.4–12 mg, supporting once-weekly subcutaneous dosing with accumulation to steady state over several weeks [1].
- starThe 48-week Phase 2 trial (Billings et al., Lancet 2025) randomized 263 adults with obesity or overweight without type 2 diabetes to once-weekly placebo or eloralintide; mean weight change from baseline was −9.5% (1 mg), −12.4% (3 mg), −17.6% (6 mg) and −20.1% (9 mg), versus −0.4% with placebo [2][3].
- starIn the same Phase 2 trial, the dose-escalation arms achieved −19.9% (6→9 mg) and −16.4% (3→9 mg) weight loss at 48 weeks, indicating that gradual titration can approach the efficacy of fixed high doses while smoothing early tolerability [2][3].
- starAdverse events in Phase 2 were predominantly mild-to-moderate gastrointestinal symptoms and fatigue that increased with dose; the 1 mg and 3 mg arms showed adverse-event rates similar to placebo, and gradual escalation lowered the incidence of gastrointestinal events [2][3].
- starOn the strength of these data, Eli Lilly reported plans to advance eloralintide into Phase 3, evaluating it both as monotherapy and in combination with the dual GIP/GLP-1 agonist tirzepatide, positioning amylin agonism as a complementary appetite-regulating mechanism [3][4].
- starMechanistic validation comes from the approved short-acting amylin analog pramlintide, which in clinical use suppresses postprandial glucagon, slows gastric emptying and promotes satiety, producing modest weight loss alongside improved glycemic control — establishing the amylin pathway as a viable target that eloralintide extends with weekly dosing [6][7].
Side Effects & Tolerability Profile
Clinical subjects transiently report mild side effects. Slowly escalating the titration dose represents the single most effective intervention to limit side effects.
- warningGastrointestinal effects (nausea, vomiting, decreased appetite, constipation or diarrhea) are the most common adverse events and increase with dose; in Phase 2 they were predominantly mild-to-moderate and were reduced by gradual dose escalation, with low-dose arms tracking close to placebo [2][3].
- warningFatigue was reported more frequently at higher doses in the Phase 2 trial, consistent with the central appetite-suppressing mechanism and reduced energy intake [2][3].
- warningBecause amylin agonism slows gastric emptying, early dosing can cause early satiety, bloating and altered absorption of co-administered oral medications, mirroring the class effect characterized for pramlintide [6][7].
- warningRapid or substantial weight loss of the magnitude seen at higher doses can carry the general risks associated with that class of therapy, including gallbladder events and loss of lean mass; long-term safety of eloralintide specifically has not yet been established beyond 48 weeks [2].
- warningAs an injectable peptide, injection-site reactions (redness, itching, transient nodules) are possible; rotating sites and proper aseptic technique reduce risk.
- warningThe very long ~13–15 day half-life means that any adverse effect, once present, resolves slowly because the drug clears over weeks rather than days — a consideration distinct from short-acting amylin analogs [1].
- warningHypoglycemia risk is low with amylin agonist monotherapy, but caution applies if combined with insulin or insulin secretagogues; in pramlintide labeling, concurrent insulin use carries a severe-hypoglycemia warning that informs amylin-class safety expectations [7].
- warningRegulatory/research status: eloralintide is NOT approved by the FDA, EMA, or any regulator; it is an investigational compound that has only completed Phase 1 and Phase 2 testing. Research-grade material is not a substitute for a prescribed product, and the figures here are educational, not medical advice [2][4].
Subcutaneous Injection Technique
Most research peptides require subcutaneous injection into fatty tissue. Never inject directly into a blood vessel or deep muscle tissue unless clinically detailed.
1. Site Selection
Common locations include the abdomen (2 inches from navel), outer upper arms, or thighs.
2. Sanitization
Thoroughly clean the selected site, stopper and vial top using 70% isopropyl alcohol prep swabs.
3. Angle & Push
Pinch the skin and insert the needle at a 45 to 90-degree angle. Depress plunger smoothly.
4. Site Rotation
Rotate injection sites continuously to avoid lipodystrophy or tissue scarring.
Frequently Asked Questions
What is the typical Eloralintide dosage?expand_more
In its Phase 2 obesity trial (NCT06230523), the Eloralintide dosage was a once-weekly subcutaneous injection of 1 mg, 3 mg, 6 mg or 9 mg, with additional arms that escalated stepwise from a low starting dose up to 9 mg to improve tolerability. Earlier Phase 1 single-dose studies tested 0.04–12 mg. Weight loss increased with dose, from roughly 9% at 1 mg to about 20% at 9 mg over 48 weeks. There is no established or approved dose because eloralintide is investigational; the figures here are an educational reference, not a prescribed regimen.
Is Eloralintide FDA approved?expand_more
No. Eloralintide (LY3841136) is not approved by the FDA, the EMA, or any other regulator. As of 2026 it is an investigational compound from Eli Lilly that has completed Phase 1 and a 48-week Phase 2 trial, with Phase 3 development planned, including evaluation alongside tirzepatide. It is not available as a prescription medicine and cannot legally be sold as a supplement. This page is educational content only and is not medical advice.
What is the half-life of Eloralintide?expand_more
Eloralintide has a very long terminal half-life of approximately 310–366 hours, or about 13–15 days, with a median time to peak concentration of roughly 72–132 hours after a subcutaneous dose. This long half-life is achieved through a C20 fatty-diacid chain that binds serum albumin, and it is the reason the drug is given only once weekly. Plasma levels accumulate over the first several weeks of weekly dosing before reaching steady state, which is why trials used gradual dose escalation.
How is Eloralintide reconstituted and administered?expand_more
Eloralintide is genuinely a subcutaneous, once-weekly injection, so the reconstitution model matches its real route. For the educational protocol on this page, a 30 mg vial is mixed with 3.0 mL of bacteriostatic water to give 10 mg/mL: draw the water slowly down the vial wall, swirl gently until clear (never shake), and refrigerate. At that concentration, 1 mg measures 10 units, 3 mg measures 30 units, 6 mg measures 60 units and 9 mg measures 90 units on a U-100 insulin syringe. Inject subcutaneously into the abdomen, thigh or upper arm once weekly, rotating sites.
Can Eloralintide be stacked with other weight-loss compounds?expand_more
In Eli Lilly's development plan, eloralintide is being studied both as monotherapy and in combination with the dual GIP/GLP-1 agonist tirzepatide, because amylin agonism is a distinct, complementary appetite-regulating mechanism. However, no combination is approved, and pairing investigational or prescription weight-loss agents can compound gastrointestinal side effects and the risks of rapid weight loss. There is no validated stacking protocol for research-grade eloralintide; any combination should be considered experimental and is outside the scope of this educational reference.
Related Guides & Tools
Step-by-step references for reconstituting, measuring, and storing Eloralintide, plus the universal dosing calculator.
Academic References & Study Citations
Briere DA, Qu H, Lansu K, He MM, Moyers JS, Coskun T, et al. Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept. Mol Metab. 2025;102:102271. doi:10.1016/j.molmet.2025.102271. View Scientific Paper →
Billings LK, Hsia S, Bays H, Tidemann-Miller B, O'Hagan J, et al. Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2025;406(10520):2631-2643. doi:10.1016/S0140-6736(25)02155-5. View Scientific Paper →
Eli Lilly and Company. Lilly's selective amylin agonist, eloralintide, demonstrated meaningful weight loss and favorable tolerability in a Phase 2 study of adults with obesity or overweight (press release). 2025. View Scientific Paper →
A Phase 2, Parallel-Group, Double-Blind Study to Investigate Weight Management With LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight. ClinicalTrials.gov identifier NCT06230523. Eli Lilly and Company. View Scientific Paper →
Billings LK, et al. Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2 trial (article record). Lancet. 2025;406(10520):2631-2643. View Scientific Paper →
Hoogwerf BJ, Doshi KB, Diab D. Pramlintide, the synthetic analogue of amylin: physiology, pathophysiology, and effects on glycemic control, body weight, and selected biomarkers of vascular risk. Vasc Health Risk Manag. 2008;4(2):355-362. View Scientific Paper →
SYMLIN (pramlintide acetate) injection, for subcutaneous use — FDA prescribing information (amylin analog class reference). U.S. Food and Drug Administration. View Scientific Paper →